Despite Few Actions On Rx Drug Promos, US FDA Increased Engagement With Stakeholders Last Year
Executive Summary
Office of Prescription Drug Promotion issued six enforcement letters and launched three research projects in 2021. There were more internal changes as the office switched to electronic submissions of promotional materials and went through year-end reorganization.
You may also be interested in...
Do Patients Understand The Term ‘Median’ In Advertising? US FDA Aims To Find Out
In first Rx advertising research project of 2023, FDA will survey consumers on how they interpret quantitative claims in DTC ads. Lilly questions design of another study examining relative importance of product information, citing FDA comments at tanezumab advisory committee.
What Trade-Offs Do Consumers And Physicians Make In Choosing Rx Drug Treatments?
US FDA study is to examine the relative importance of product information, such as efficacy, risk and patient preference claims, in the treatment preferences of consumers and physicians.
Rx Drug Promotion: Inclusion Of Extensive Risk Info In Twitter, Google Ads Has Potential Drawback
US FDA study of character-space-limited prescription drug communications finds consumers may be less likely to click on a link for more risk information if the promo already has substantial details.